Robert H. Murdock

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Salix Pharmaceuticals Ltd. develops and commercializes prescription drugs and medical devices used in the treatment of gastrointestinal diseases, endocrinology, hepatology, colorectal surgery, and internal medicine. It offers Anusol, Apriso, Colazal, Deflux, Diuril, Fenoglide, MoviPrep, Pepcid, Solesta, and Zegerid. The company was founded by randy W. Hamilton and Lorin K. Johnson in1989 and is headquartered in Bridgewater, NJ.